{"id":"NCT00863304","sponsor":"Pfizer","briefTitle":"Tanezumab in Osteoarthritis of the Hip or Knee (2)","officialTitle":"A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO AND NAPROXEN CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06-09","primaryCompletion":"2010-04-27","completion":"2010-08-16","firstPosted":"2009-03-17","resultsPosted":"2021-05-17","lastUpdate":"2021-05-17"},"enrollment":849,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis"],"interventions":[{"type":"BIOLOGICAL","name":"tanezumab 10 mg","otherNames":[]},{"type":"BIOLOGICAL","name":"tanezumab 5 mg","otherNames":[]},{"type":"DRUG","name":"naproxen","otherNames":[]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"ACTIVE_COMPARATOR"},{"label":"4","type":"PLACEBO_COMPARATOR"}],"summary":"Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis","primaryOutcome":{"measure":"Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF)","timeFrame":"Baseline, Week 16","effectByArm":[{"arm":"Placebo","deltaMin":7.41,"sd":1.38},{"arm":"Tanezumab 5 mg + Placebo","deltaMin":7.27,"sd":1.38},{"arm":"Tanezumab 10 mg + Placebo","deltaMin":7.37,"sd":1.39},{"arm":"Naproxen + Placebo","deltaMin":7.3,"sd":1.41}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"0.002"},{"comp":"OG000 vs OG003","p":"0.090"},{"comp":"OG001 vs OG003","p":"0.009"},{"comp":"OG002 vs OG003","p":"0.175"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":95,"countries":["United States"]},"refs":{"pmids":["37460782","30936738","25274899"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091018&StudyName=Tanezumab%20in%20osteoarthritis%20of%20the%20hip%20or%20knee%20%282%29"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":209},"commonTop":["Arthralgia","Paraesthesia","Headache","Urinary tract infection","Oedema peripheral"]}}